Objective. To give an overview of the recommendations for the use of anti-TNF-a therapy in AS in 23 countries worldwide
Introduction
AS is a chronic, progressive inflammatory, rheumatic disease that generally starts in the second or third decade of life [13] . The most characteristic features of AS are inflammatory back pain (IBP) due to sacroiliitis and spondylitis, and the formation of syndesmophytes leading to ankylosis of the spine [1, 4] . In addition, AS is frequently associated with enthesitis, acute anterior uveitis, inflammatory bowel disease (IBD), psoriasis, peripheral (oligo)arthritis predominantly of the lower extremities, and cardiovascular and pulmonary abnormalities [1, 5, 6] .
For decades, AS was mainly treated with NSAIDs, physiotherapy and to a lesser extent with DMARDs [3, 4] . And this is still the basis for treatment according to the Assessment of SpondyloArthritis International Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of AS [1] . Even though NSAIDs often give quick symptomatic relief [7] , the effects on the longterm outcome are limited and there are reservations with safety in relation to long-term use [2, 7, 8] . Moreover, DMARDs are largely ineffective in axial AS and have limited efficacy on peripheral arthritis in AS [3, 7, 8] . The treatment armamentarium is broadened since the discovery of anti-TNF-a agents as an effective therapy. The anti-TNF-a agents infliximab [8, 9] , etanercept [10, 11] , adalimumab [12] and golimumab [13] have shown to be effective in the treatment of AS in short-term as well as intermediate to long-term evaluations [2, 14] .
Anti-TNF-a agents are very effective in the treatment of AS; nevertheless, they are associated with high costs and risks of side effects and might not be suitable for all patients. Therefore, it is important that recommendations are available to support the appropriate use of anti-TNF-a agents within individual countries.
In 2003, the ASAS proposed recommendations for the use of anti-TNF-a treatment in AS for rheumatologists and other experts in the management of AS, as well as payers [3, 14] . There was an update of the recommendations in 2006 [15] . Many countries developed national guidelines, whether or not based on the ASAS recommendations. The aim of the present report is to give an overview of the recommendations for the use of anti-TNF-a therapy in AS in 23 countries worldwide, with a focus on the similarities and differences compared with the ASAS recommendations. In concordance with the advice of EULAR, we use the general term of recommendations throughout the manuscript, although some countries publish their recommendations as guidelines.
Methods
The recommendations of the following countries (presented alphabetically grouped by continent) were presented and translated: Australia, Hong Kong, Korea, Canada, Colombia, Mexico, Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland and the UK. A summary of the translated recommendations was sent to ASAS members from the specific countries included in this overview. They were asked to check the correctness of the summary. The recommendations were compared with the 2006 version of the ASAS recommendations [15] as a standard to be able to easily compare discrepancies.
ASAS recommendations
The ASAS recommendations are divided into the following three parts: patient selection for initiation of treatment including diagnosis, disease activity, previous treatment and contraindications; assessment of disease; and assessment of response (Table 1) . Table 2 gives an overview of the recommendations of the 23 countries (references of the recommendations in appendix 1, available as supplementary data at Rheumatology Online). They are presented alphabetically grouped by continent. The recommendations of Canada, Mexico, France, Italy, Portugal, Spain and Sweden (n = 7) (Table 2) were developed by the professional rheumatologic community as treatment recommendations. In Australia, Hong Kong, Korea, Colombia, Belgium, Finland, Greece, Norway, Poland and Switzerland (n = 10) (Table 2), the recommendations were developed for reimbursement purposes. The recommendations of the Czech Republic, Germany, Hungary, the Netherlands, the UK and Slovakia (n = 6) (Table 2) were developed for both purposes.
Results

Diagnosis
According to the ASAS recommendations, patients should normally fulfil the modified New York criteria for AS (Table 1) [15] . Most recommendations (n = 16) follow the ASAS recommendations and qualify patients for treatment if they fulfil the modified New York criteria [16] . In five recommendations, MRI and/or CT, instead of X-rays, are approved to reveal sacroiliitis [16] . In Hong Kong and Colombia, a diagnosis of SpA according to the Amor or ESSG criteria is sufficient for the diagnostic part for initiation of anti-TNF-a therapy (Table 2 ).
Disease activity
The ASAS recommendations define active AS as having active disease for >4 weeks based on a BASDAI score 54 (scale 010) and an expert opinion of active AS (Table 1 ) [15] . According to all recommendations, except the Finnish recommendation, disease activity should be measured with the BASDAI. In 19 recommendations, the disease activity is qualified as high when the BASDAI is 54. In two other recommendations (Hong Kong and Norway), the BASDAI is also used to measure disease activity, but no qualification of active disease is given. An expert opinion to determine disease activity is required in 13 countries (Table 2) .
In eight recommendations, additional assessments of disease activity are required, such as laboratory parameters for inflammation (CRP and/or ESR), (spinal) pain [visual analogue scale (VAS)] (n = 4), patient and physician global health (n = 2 and n = 1, respectively), and/or inflammation on MRI (n = 1), or limitation in spinal mobility (n = 1) ( Table 2 ). In particular, the request for additional elevated acute-phase reactants or inflammation on MRI increases the threshold to start a TNF-blocker substantially. In one instance (Hong Kong), a large increase is required (ESR > 50 mm/h or CRP > 50 mg/l). Moreover, the requirement for limitation in spinal mobility is remarkable, as this can be caused by the severity of the disease without active inflammation.
Failure of standard treatment ASAS offers a description of conventional treatment failure specified for the predominant localization of the disease (axial, peripheral arthritis and enthesitis) ( Table 1) . Most recommendations follow the ASAS recommendations and give specified descriptions of treatment failure. In general, the recommendations describe failure of conventional treatment for predominantly axial localization as failure of two or more NSAIDs administered for a period of 13 months (n = 18). In Hong Kong, Canada and France, patients should fail at least three NSAIDs. Conventional treatment failure for a predominantly peripheral localization is in 18 recommendations described as a failure of one or two DMARDs (in most recommendations specified as MTX and/or SSZ) administered for a period of 23 months, and as a failure of IA injections of CSs www.rheumatology.oxfordjournals.org (n = 16). Conventional treatment failure of CS injections for enthesitis is described in 12 recommendations (Table 2) .
Contraindications
To minimize treatment risks, ASAS has specified a list of contraindications (Table 1 ) basically similar to contraindications of the treatment of anti-TNF-a therapy for other indications [15] . Almost all recommendations (n = 17) list active infections, especially tuberculosis (TB), as contraindications. Several recommendations mention some types of malignancy or pre-malignancy (n = 10), a history of lupus (n = 8), multiple sclerosis or other demyelinating diseases (n = 11) and pregnancy/breastfeeding (n = 9) as contraindications, in accordance with the ASAS recommendations. A frequently mentioned contraindication (n = 11) not referred to in the ASAS recommendations [15] is heart failure Stages 34 as defined by the New York Heart Association (NYHA) [17] . Remarkably, the recommendations of the Czech Republic and Slovakia report that an advanced or terminal radiographic stage of the disease is a contraindication for applying anti-TNF-a therapy. Four recommendations do not mention contraindications at all.
Monitoring and withdrawal ASAS recommends using the ASAS core set for daily practice [18] and the BASDAI to assess the activity of the disease (Table 1 ) [15] . Most countries (n = 19) recommend the ASAS core set for daily practice as well, or at least a part of the ASAS core set. However, four countries do not specify how to assess the disease (Table 2 ).
An assessment of the treatment response should be conducted 612 weeks after the start of the treatment, according to ASAS (Table 1) [15] . In 16 recommendations, the same time frame is advised. However, in seven recommendations the response is assessed after >12 weeks (range 1416 weeks).
At this assessment point, a decision should be made about either continuation or discontinuation of anti-TNF-a therapy. ASAS advises considering discontinuation in patients not showing a 50% relative or absolute change of 2 cm (scale 010 cm) in the BASDAI score [15] . Eighteen recommendations use these criteria to determine a good treatment response. In some recommendations other criteria to assess response to treatment are obligatory, such as normalized or improved lab tests (n = 3) and improvement in pain (n = 2) or BASDAI <4 (n = 1). Furthermore, ASAS advises a positive opinion by the expert to continue treatment. This criterion is used in 14 recommendations as well.
Discussion and conclusion
This report provides an overview of the recommendations developed in 23 countries across the world. ASAS developed recommendations for the management of anti-TNF-a therapy in patients with AS [3, 15] . As internationally developed recommendations, the ASAS recommendations might contribute to comparable access with anti-TNF-a treatment across countries [19] .
Indeed, this aim is (largely) reached, since the recommendations in AS are quite similar worldwide, in contrast to the recommendations in RA, which vary greatly between countries in Europe [19] . This can be explained by the lack of European guidance for initiation of anti-TNF-a therapy in RA [19] , unlike the situation in AS [15] . Another explanation might be the considerably varying goals of RA treatment with anti-TNF-a agents [19] . Other possible explanations for the differences in recommendations across countries that apply to both RA and AS are variations regarding different methods for funding health-care provision and the level of recognition of recommendations [19] .
Despite the similarities between the recommendations in AS across countries, differences exist. These differences are mostly based on the fact that some countries use objective assessment, such as acute-phase reactants, to measure disease activity for initiation and to monitor treatment response. This puts a major limitation on access to TNF-a blockers for patients in these countries, as only about half of the patients with active disease have elevated acute-phase reactants [20] . Although patients with elevated acute-phase reactants have a higher likelihood to show response, this difference is too small to withhold patients with a normal acute-phase reactant treatment with TNF-a blockers. Other differences exist in the required pre-treatment for NSAIDs (more and/or longer) and DMARDs (also required in axial disease and not only SSZ in peripheral disease). Moreover, several countries evaluate the efficacy of treatment after 512 weeks.
In conclusion, it can be said that despite some differences, there is general consensus about the recommendations to use anti-TNF-a therapy in AS across the world, except for the stricter requirement of objective signs of inflammation in some countries. The observation that most national recommendations follow the international ASAS recommendations seems to indicate that the latter are widely accepted and implemented. The information acquired by this comparison will also be taken into account in the next update of the ASAS recommendations.
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the correctness of the (translated) summaries of the national recommendations.
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